<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">oncotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский онкологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian journal of oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1814-4861</issn><issn pub-type="epub">2312-3168</issn><publisher><publisher-name>Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">oncotomsk-102</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group></article-categories><title-group><article-title>ОСЛОЖНЕНИЯ ИЗОЛИРОВАННОЙ РЕГИОНАРНОЙ ХИМИОПЕРФУЗИИ КОНЕЧНОСТЕЙ</article-title><trans-title-group xml:lang="en"><trans-title>COMPLICATIONS OF ISOLATED REGIONAL LIMB CHEMOPERFUSION</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гафтон</surname><given-names>Г. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Gafton</surname><given-names>G. I.</given-names></name></name-alternatives><email xlink:type="simple">ssemiletov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сенчик</surname><given-names>К. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Senchik</surname><given-names>К. Yu.</given-names></name></name-alternatives><email xlink:type="simple">ssemiletov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гафтон</surname><given-names>И.</given-names></name><name name-style="western" xml:lang="en"><surname>Gafton</surname><given-names>I. G.</given-names></name></name-alternatives><email xlink:type="simple">ssemiletov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Розенгард</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Rozengard</surname><given-names>S. A.</given-names></name></name-alternatives><email xlink:type="simple">ssemiletov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петров</surname><given-names>В.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrov</surname><given-names>V. G.</given-names></name></name-alternatives><email xlink:type="simple">ssemiletov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семиглазов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Semiglazov</surname><given-names>V. V.</given-names></name></name-alternatives><email xlink:type="simple">ssemiletov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семилетова</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Semiletova</surname><given-names>Yu. V.</given-names></name></name-alternatives><email xlink:type="simple">ssemiletov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зиновьев</surname><given-names>Г. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zinovyev</surname><given-names>G. V.</given-names></name></name-alternatives><email xlink:type="simple">ssemiletov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НИИ онкологии имени Н.Н. Петрова,  Санкт-Петербург</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.N. Petrov Research Institute of Oncology, St-Petersburg</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>16</day><month>02</month><year>2016</year></pub-date><volume>1</volume><issue>1</issue><fpage>13</fpage><lpage>18</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гафтон Г.И., Сенчик К.Ю., Гафтон И.G., Розенгард С.А., Петров В.G., Семиглазов В.В., Семилетова Ю.В., Зиновьев Г.В., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Гафтон Г.И., Сенчик К.Ю., Гафтон И., Розенгард С.А., Петров В., Семиглазов В.В., Семилетова Ю.В., Зиновьев Г.В.</copyright-holder><copyright-holder xml:lang="en">Gafton G.I., Senchik К.Y., Gafton I.G., Rozengard S.A., Petrov V.G., Semiglazov V.V., Semiletova Y.V., Zinovyev G.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.siboncoj.ru/jour/article/view/102">https://www.siboncoj.ru/jour/article/view/102</self-uri><abstract><p>В настоящее время активно изучаются методы локального воздействия на местно-диссеминированные опухоли конечностей, позволяющие избежать калечащей операции и сохранить высокое качество жизни больного. Одной из таких методик является изолированная регионарная химиоперфузия конечностей. Мы изучили данные по 70 больным, которым в отделении общей онко логии НИИ онкологии им. Н.Н. Петрова в период с 2004 по 2014  выполнена изолированная химиоперфузия по поводу местно распространенных сарком мягких тканей, а также транзитных метастазов меланомы конечностей. Представлен анализ возможных осложнений ИРП, причины их возникновения и возможные пути профилактики.</p></abstract><trans-abstract xml:lang="en"><p>Currently, the methods of delivering high local doses of chemotherapy to locally-advanced tumors of the extremities, while avoiding systemic toxicity, are actively investigated. Isolated regional limb chemoperfusion is one of these methods. From 2004 to 2014, a total of 70 patients underwent isolated limb perfusion (ILP) for locally-advanced soft tissue sarcoma and transit metastases of extremity melanoma. Complications of ILP, causes of their occurrence and preventive measures were analyzed.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>изолированная регионарная химиоперфузия</kwd><kwd>меланома</kwd><kwd>саркомы</kwd><kwd>осложнения</kwd></kwd-group><kwd-group xml:lang="en"><kwd>isolated regional limb chemoperfusion</kwd><kwd>melanoma</kwd><kwd>sarcoma</kwd><kwd>complications</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Гафтон Г.И., Пхакадзе Н.Р., Сенчик К.Ю., Гельфольд В.М. Перспективные методы терапии больных саркомами мягких тканей конечностей (изолированная регионарная перфузия, локальная гипертермия) // Практическая онкология. 2004. Т. 5, № 4. С. 276–284. Г.И. Гафтон, К.Ю. Сенчик, И. Гафтон И ДР.</mixed-citation><mixed-citation xml:lang="en">Gafton G.I., Phakadze N.R., Senchik K.Ju., Gel'fol'd V.M. Promising approaches to therapy of extremity soft tissue sarcomas (isolated regional perfusion, local hyperthermia) // Prakticheskaja onkologija. 2004. Vol. 5 (4). P. 276–284.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Переводчикова Н.И. Руководство по химиотерапии. М., 2005. С. 336–343.</mixed-citation><mixed-citation xml:lang="en">Perevodchikova N.I. Guide to chemotherapy. М., 2005. P. 336–343.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Тришкин В.А., Гафтон Г.И., Канаев С.В., Тришкина Е.В., Ильин Н.В., Ергнян С.М. Оценка эффективности комбинированного лечения больных первичными саркомами мягких тканей конечностей, подвергшихся сберегательным операциям // Вопросы онкологии. 2009. Т. 55, № 6. С. 722–726.</mixed-citation><mixed-citation xml:lang="en">Trishkin V.A., Gafton G.I., Kanaev S.V., Trishkina E.V., Il'in N.V., Ergnjan S.M. Assessment of treatment effectiveness of primary extremity soft tissue sarcomas after limb saving surgery // Voprosy onkologii. 2009. Vol. 55 (6). P. 722–726.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Alexander R.H. Jr., Fraker D.L., Bartlett D.L., Libutti S.K., Steinberg S.M., Soriano P., Beresnev T. Analysis of Factors Influencing Outcome in Patients With In-Transit Malignant Melanoma Undergoing Isolated Limb Perfusion Using Modern Treatment Parameters // J. Clin. Oncol. 2010 Vol. 28 (1). P. 114–118. doi: 10.1200/JCO.2009.23.7511.</mixed-citation><mixed-citation xml:lang="en">Alexander R.H. Jr., Fraker D.L., Bartlett D.L., Libutti S.K., Steinberg S.M., Soriano P., Beresnev T. Analysis of Factors Influencing Outcome in Patients With In-Transit Malignant Melanoma Undergoing Isolated Limb Perfusion Using Modern Treatment Parameters // J. Clin. Oncol. 2010 Vol. 28 (1). P. 114–118. doi: 10.1200/JCO.2009.23.7511.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Beasley G.M., Caudle A., Petersen R.P., McMahon N.S., Padussis J., Mosca P.J., Zager J.S., Hochwald S.N., Grobmyer S.R., Delman K.A., Andtbacka R.H., Noyes R.D., Kane J.M., Seigler H., Pruitt S.K., Ross M.I., Tyler D.S. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US // J. Am. Coll. Surg. 2009. Vol. 208 (5). P. 706–715. doi: 10.1016/j.jamcollsurg.2008.12.019.</mixed-citation><mixed-citation xml:lang="en">Beasley G.M., Caudle A., Petersen R.P., McMahon N.S., Padussis J., Mosca P.J., Zager J.S., Hochwald S.N., Grobmyer S.R., Delman K.A., Andtbacka R.H., Noyes R.D., Kane J.M., Seigler H., Pruitt S.K., Ross M.I., Tyler D.S. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US // J. Am. Coll. Surg. 2009. Vol. 208 (5). P. 706–715. doi: 10.1016/j.jamcollsurg.2008.12.019.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bonvalot S., Laplanche A., Lejeune F., Stoeckle E., Le Péchoux C., Vanel D., Terrier P., Lumbroso J., Ricard M., Antoni G., Cavalcanti A., Robert C., Lassau N., Blay J.Y., Le Cesne A. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alfa be better? // Ann. Oncol. 2005. Vol. 16 (7). P. 1061–1068.</mixed-citation><mixed-citation xml:lang="en">Bonvalot S., Laplanche A., Lejeune F., Stoeckle E., Le Péchoux C., Vanel D., Terrier P., Lumbroso J., Ricard M., Antoni G., Cavalcanti A., Robert C., Lassau N., Blay J.Y., Le Cesne A. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alfa be better? // Ann. Oncol. 2005. Vol. 16 (7). P. 1061–1068.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng T.Y., Grubbs E., Abdul-Wahab O., Leu S.Y., Hung C.F., Petros W., Aloia T., Fedrau R., Pruitt S., Colvin M., Friedman H., Tyler D. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion // Am. J. Surg. 2003. Vol. 186 (5). P. 460–467.</mixed-citation><mixed-citation xml:lang="en">Cheng T.Y., Grubbs E., Abdul-Wahab O., Leu S.Y., Hung C.F., Petros W., Aloia T., Fedrau R., Pruitt S., Colvin M., Friedman H., Tyler D. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion // Am. J. Surg. 2003. Vol. 186 (5). P. 460–467.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Deroose J.P., Eggermont A.M., van Geel A.N., de Wilt J.H., Burger J.W., Verhoef C. 20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters // Ann. Surg. Oncol. 2012. Vol. 19 (2). P. 627–635. doi: 10.1245/s10434-011-2030-7.</mixed-citation><mixed-citation xml:lang="en">Deroose J.P., Eggermont A.M., van Geel A.N., de Wilt J.H., Burger J.W., Verhoef C. 20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters // Ann. Surg. Oncol. 2012. Vol. 19 (2). P. 627–635. doi: 10.1245/s10434-011-2030-7.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">McMahon N., Cheng T.Y., Beasley G.M., Spasojevic I., Petros W., Augustine C.K., Zipfel P., Padussis J.C., Sanders G., Tyler D.S. Optimizing Melphalan Pharmacocinetics in Regional Melanoma Therapy: Does Correcting for Ideal Body Weight Alter Regioal Response of Toxicity? // Ann. Surg. Oncol. 2009. Vol. 16 (4). P. 953–961. doi: 10.1245/s10434008-0288-1.</mixed-citation><mixed-citation xml:lang="en">McMahon N., Cheng T.Y., Beasley G.M., Spasojevic I., Petros W., Augustine C.K., Zipfel P., Padussis J.C., Sanders G., Tyler D.S. Optimizing Melphalan Pharmacocinetics in Regional Melanoma Therapy: Does Correcting for Ideal Body Weight Alter Regioal Response of Toxicity? // Ann. Surg. Oncol. 2009. Vol. 16 (4). P. 953–961. doi: 10.1245/s10434008-0288-1.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Pace M., Gattai R., Matteini M., Mascitelli E.M., Bechi P. Toxciti and morbility after isolated lover limb pervusion in 242 chemo-hyperthermal treatment for cutaneous melanoma: The experience of the Tuscan Reference Centre // J. Exp. Clin. Cancer Res. 2008. Vol. 27. P. 67. doi: 10.1186/1756-9966-27-67.</mixed-citation><mixed-citation xml:lang="en">Pace M., Gattai R., Matteini M., Mascitelli E.M., Bechi P. Toxciti and morbility after isolated lover limb pervusion in 242 chemo-hyperthermal treatment for cutaneous melanoma: The experience of the Tuscan Reference Centre // J. Exp. Clin. Cancer Res. 2008. Vol. 27. P. 67. doi: 10.1186/1756-9966-27-67.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Rossi C.R., Foletto M., Mocellin S., Pilati P., Lise M. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases // Ann. Surg. Oncol. 2004. Vol. 11 (2). P. 173–177.</mixed-citation><mixed-citation xml:lang="en">Rossi C.R., Foletto M., Mocellin S., Pilati P., Lise M. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases // Ann. Surg. Oncol. 2004. Vol. 11 (2). P. 173–177.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Wieberdink J., Benckhuysen C., Braat R.P., van Slooten E.A., Olthuis G.A. Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions // Eur. J. Cancer Clin. Oncol. 1982. Vol. 18 (10). P. 905–910.</mixed-citation><mixed-citation xml:lang="en">Wieberdink J., Benckhuysen C., Braat R.P., van Slooten E.A., Olthuis G.A. Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions // Eur. J. Cancer Clin. Oncol. 1982. Vol. 18 (10). P. 905–910.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
